Comparison of carbamazepine alone and in combination with baclofen in trigeminal neuralgia

Erum Rehman; Amna Umar; Shafaq  Zafar; Amber Javaid; Riaz Nasim; Muhammad Younas

doi:10.53730/ijhs.v6nS7.13754

Authors

Erum Rehman Lecturer Pharmacology department Peshawar Medical College, Peshawar Riphah International University, Islamabad
Amna Umar Pharmacology departmentPeshawar Medical College, Peshawar Riphah International University, Islamabad
Shafaq Zafar Associate Professor Pharmacology department Peshawar Medical College, Peshawar Riphah International University, Islamabad
Amber Javaid Assistant Professor Pharmacology department PeshawarMedical College, Peshawar Riphah International University, Islamabad
Riaz Nasim Professor/HOD Pharmacology department Peshawar Medical College, Peshawar Riphah International University, Islamabad
Muhammad Younas Associate Professor Oral Medicine department Peshawar Dental College and Hospital, Peshawar Riphah International University, Islamabad

Keywords:

Trigeminal, patients.Carbamazepine, Dentistry

Abstract

Introduction: Trigeminal neuralgia is a type of neuropathic facial pain that is characterized by unilateral paroxysmal pain that affects one or more trigeminal nerve divisions and is brought on by unimportant stimuli. People over the age of 40 are more likely to get it, and women are more frequently affected than males. Trigeminal neuralgia has been treated with a variety of drugs, including carbamazepine, oxcarbazepine, baclofen, lamotrigine, levetiracetam, gabapentin, sodium valproate, botulinum toxin-A injection, and surgical. OBJECTIVES: The current study's objective was to assess the efficacy of carbamazepine in treating trigeminal neuralgia in individuals both on its own and in combination with baclofen. METHODS: A randomized control trial was conductedat Khyber College of Dentistry and Peshawar Dental College among the patients of trigeminal neuralgia presenting to OPD. Total 60patients were randomly selected into two groups, each group had 30 patients.Carbamazepine was given to the Group A in the dose range of 300-600mg TDSwhereas, Carbamazepine 300mg TDS along with Baclofen in the dose range of 10-20 mg B.D was given to Group B. The two groups were given the drugs for a period of thirty days. The data was collected through a self-structuredquestionnaire.

Downloads

Download data is not yet available.

References

Puri N, Rathore A, Dharmdeep G, Vairagare S, Prasad BR, Priyadarshini R, et al. A clinical study on comparative evaluation of the effectiveness of carbamazepine and combination of carbamazepine with baclofen or capsaicin in the management of trigeminal neuralgia. 2018;24(2):95-9.

Di Stefano G, Truini A, Cruccu GJD. Current and innovative pharmacological options to treat typical and atypical trigeminal neuralgia. 2018;78(14):1433-42.

Pergolizzi Jr JV, Gharibo C, Magnusson P, Breve F, LeQuang JA, Varrassi GJEOoP. Pharmacotherapeutic management of trigeminal neuropathic pain: an update. 2022;23(10):1155-64.

Allam AK, Sharma H, Larkin MB, Viswanathan AJNC. Trigeminal Neuralgia: Diagnosis and Treatment. 2023;41(1):107-21.

Asdullah M, Salati NA, Aggarwal A, Tiwari R, Verma P, Khwaja KJJJoAM, et al. Comparing the Efficacy of Carbamazepine and Gabapentin in the Management of Trigeminal Neuralgia: A Hospital based Clinical Study. 2021;9(9):38-41.

Jones MR, Urits I, Ehrhardt KP, Cefalu JN, Kendrick JB, Park DJ, et al. A comprehensive review of trigeminal neuralgia. 2019;23(10):1-7.

Kaur B, Dhir PJJoIAoOM, Radiology. Evaluation of the efficacy of carbamazepine and gabapentin in the management of trigeminal neuralgia: A clinical study. 2018;30(3):253.

Lambru G, Zakrzewska J, Matharu MJPN. Trigeminal neuralgia: a practical guide. 2021;21(5):392-402.

Agarwal A, Tripathi M. Pharmacotherapy of Trigeminal Neuralgia. Handbook of Trigeminal Neuralgia: Springer; 2019. p. 63-8.

Alves AMF. Trigeminal Neuralgia: Pharmacological and Surgical Treatment. 2022.

Penn MC, Choi W, Brasfield K, Wu K, Briggs RG, Dallapiazza R, et al. A Review of Medical and Surgical Options for the Treatment of Facial Pain. 2022.

Bendtsen L, Zakrzewska JM, Heinskou TB, Hodaie M, Leal PRL, Nurmikko T, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. 2020;19(9):784-96.

Luitel A, Rimal J, Maharjan I, Regmee P, Adhikari S, Tamang RJJNDA. Management of trigeminal neuralgia: A narrative review. 2021;21(32):67-74.

Lake E. Medication Management. Trigeminal Nerve Pain: Springer; 2021. p. 77-87.

Suresh KJJohrs. An overview of randomization techniques: an unbiased assessment of outcome in clinical research. 2011;4(1):8.

Breivik EK, Björnsson GA, Skovlund EJTCjop. A comparison of pain rating scales by sampling from clinical trial data. 2000;16(1):22-8.

Lundeberg T, Lund I, Dahlin L, Borg E, Gustafsson C, Sandin L, et al. Reliability and responsiveness of three different pain assessments. 2001;33(6):279-83.

Brameli A, Kachko L, Eidlitz‐Markus TJHTJoH, Pain F. Trigeminal neuralgia in children and adolescents: experience of a tertiary pediatric headache clinic. 2021;61(1):137-42.

Jay GW, Barkin RLJD-a-M. Trigeminal neuralgia and persistent idiopathic facial pain (atypical facial pain). 2022;68(6):101302.

Venda Nova C, Ni Riordain R, Baker SR, Zakrzewska JMJEJoP. An international Delphi survey and consensus meeting to define the core outcome set for trigeminal neuralgia clinical trials. 2022.

Liu Q, Fan W, He H, Huang FJOD. The role of peripheral opioid receptors in orofacial pain. 2021;27(5):1106-14.

Puri J, Bellinger LL, Kramer PRJJocp. Estrogen in cycling rats alters gene expression in the temporomandibular joint, trigeminal ganglia and trigeminal subnucleus caudalis/upper cervical cord junction. 2011;226(12):3169-80.

Steardo L, Leo A, Marano EJEn. Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. 1984;23(1):51-5.